How Metformin Affects Various Malignancies by Means of MicroRNAs: a Brief Review

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2021 Apr 14

PMID 33849540

Citations 15

Authors

Nahid Alimoradi

Negar Firouzabadi

Reihaneh Fatehi

Affiliations

Soon will be listed here.

Abstract

Metformin known as the first-line orally prescribed drug for lowering blood glucose in type II diabetes (T2DM) has recently found various therapeutic applications including in cancer. Metformin has been studied for its influences in prevention and treatment of cancer through multiple mechanisms such as microRNA (miR) regulation. Alteration in the expression of miRs by metformin may play an important role in the treatment of various cancers. MiRs are single-stranded RNAs that are involved in gene regulation. By binding to the 3'UTR of target mRNAs, miRs influence protein levels. Irregularities in the expression of miRs that control the expression of oncogenes and tumor suppressor genes are associated with the onset and progression of cancer. Metformin may possess an effect on tumor prevention and progression by modifying miR expression and downstream pathways. Here, we summarize the effect of metformin on different types of cancer by regulating the expression of various miRs and the associated downstream molecules.

Citing Articles

Metformin Exhibits Anti-Inflammatory Effects by Regulating microRNA-451/CXCL16 and B Cell Leukemia/Lymphoma 2 in Patients With Osteoarthritis.

Alimoradi N, Ramezani A, Tahami M, Firouzabadi N ACR Open Rheumatol. 2024; 7(1):e11755.

PMID: 39435687 PMC: 11694140. DOI: 10.1002/acr2.11755.

Non-coding RNAs as potential targets in metformin therapy for cancer.

Zhang Y, Wu Y, Liu Z, Yang K, Lin H, Xiong K Cancer Cell Int. 2024; 24(1):333.

PMID: 39354464 PMC: 11445969. DOI: 10.1186/s12935-024-03516-w.

A Narrative Review: Repurposing Metformin as a Potential Therapeutic Agent for Oral Cancer.

Li J, Hsin P, Hsiao Y, Chen B, Zhuang Z, Lee C Cancers (Basel). 2024; 16(17).

PMID: 39272875 PMC: 11394296. DOI: 10.3390/cancers16173017.

Metformin and its potential influence on cell fate decision between apoptosis and senescence in cancer, with a special emphasis on glioblastoma.

Hajimohammadebrahim-Ketabforoush M, Zali A, Shahmohammadi M, Hamidieh A Front Oncol. 2024; 14:1455492.

PMID: 39267853 PMC: 11390356. DOI: 10.3389/fonc.2024.1455492.

Dextran sulfate inhibits proliferation and metastasis of human gastric cancer cells via miR-34c-5p.

Zhao Y, Ma Q, Gao W, Li Z, Yu G, Li B Heliyon. 2024; 10(15):e34859.

PMID: 39157392 PMC: 11327518. DOI: 10.1016/j.heliyon.2024.e34859.

References

Sun Y, Zhang T, Wang C, Jin X, Jia C, Yu S . MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2. PLoS One. 2015; 10(4):e0119783. PMC: 4391776. DOI: 10.1371/journal.pone.0119783. View

Kawanami T, Takiguchi S, Ikeda N, Funakoshi A . A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells. Oncol Rep. 2011; 27(3):867-72. DOI: 10.3892/or.2011.1597. View

Kato K, Iwama H, Yamashita T, Kobayashi K, Fujihara S, Fujimori T . The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin. Oncol Rep. 2015; 35(3):1582-92. DOI: 10.3892/or.2015.4496. View

Guo W, Tan W, Liu S, Huang X, Lin J, Liang R . MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. Tumour Biol. 2015; 36(11):9049-57. DOI: 10.1007/s13277-015-3644-3. View

Re M, Magliulo G, Gioacchini F, Bajraktari A, Bertini A, Ceka A . Expression Levels and Clinical Significance of miR-21-5p, miR-let-7a, and miR-34c-5p in Laryngeal Squamous Cell Carcinoma. Biomed Res Int. 2017; 2017:3921258. PMC: 5610801. DOI: 10.1155/2017/3921258. View

Guo M, Zhou J, Huang W . Metformin alleviates endometrial hyperplasia through the UCA1/miR‑144/TGF‑β1/AKT signaling pathway. Int J Mol Med. 2020; 45(2):623-633. DOI: 10.3892/ijmm.2019.4438. View

Zhuang Y, Miskimins W . Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 2008; 3:18. PMC: 2613390. DOI: 10.1186/1750-2187-3-18. View

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P . The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. DOI: 10.1038/sj.onc.1211024. View

Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Quirantes R, Segura-Carretero A, Micol V . Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. Cell Cycle. 2012; 11(6):1235-46. DOI: 10.4161/cc.11.6.19665. View

10.

McCarty M . Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression. Med Hypotheses. 2011; 78(2):262-9. DOI: 10.1016/j.mehy.2011.10.041. View

11.

Yang L, Bai H, Deng Y, Fan L . High MALAT1 expression predicts a poor prognosis of cervical cancer and promotes cancer cell growth and invasion. Eur Rev Med Pharmacol Sci. 2015; 19(17):3187-93. View

12.

Antolin S, Calvo L, Blanco-Calvo M, Santiago M, Lorenzo-Patino M, Haz-Conde M . Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer. 2015; 15:297. PMC: 4405843. DOI: 10.1186/s12885-015-1238-5. View

13.

Mannaerts G, Van Veldhoven P, Casteels M . Peroxisomal lipid degradation via beta- and alpha-oxidation in mammals. Cell Biochem Biophys. 2001; 32 Spring:73-87. DOI: 10.1385/cbb:32:1-3:73. View

14.

Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K . Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology. 2003; 37(3):534-43. DOI: 10.1053/jhep.2003.50112. View

15.

Hermeking H . The miR-34 family in cancer and apoptosis. Cell Death Differ. 2009; 17(2):193-9. DOI: 10.1038/cdd.2009.56. View

16.

Peng F, Li T, Wang K, Xiao G, Wang J, Zhao H . H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis. 2017; 8(1):e2569. PMC: 5386357. DOI: 10.1038/cddis.2016.438. View

17.

Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K, Kosma V . Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer. 1999; 80(12):2001-7. PMC: 2363145. DOI: 10.1038/sj.bjc.6690634. View

18.

Demirsoy I, Yolal Ertural D, Balci S, Cinkir U, Sezer K, Tamer L . Profiles of Circulating MiRNAs Following Metformin Treatment in Patients with Type 2 Diabetes. J Med Biochem. 2018; 37(4):499-506. PMC: 6298473. DOI: 10.2478/jomb-2018-0009. View

19.

Bao X, Zhao L, Guan H, Li F . Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma. Cell Death Dis. 2018; 9(6):611. PMC: 5966512. DOI: 10.1038/s41419-018-0620-z. View

20.

Wang C, Ding M, Xia M, Chen S, Le A, Soto-Gil R . A Five-miRNA Panel Identified From a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients. EBioMedicine. 2015; 2(10):1377-85. PMC: 4634198. DOI: 10.1016/j.ebiom.2015.07.034. View